NCT07196930 Valvular Heart Disease in Women Registry
| NCT ID | NCT07196930 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Valvular Heart Disease in Women Registry |
| Condition | Valve Disease, Heart |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2024-04-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity/mortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.
Eligibility Criteria
Inclusion Criteria: * Adult patients with diagnosis of any VHD according to the current ESC guidelines. * Admission to the VHD-W Registry collaborating center. Exclusion Criteria: * Age less than 18 years old. * Inability to provide informed consent per local institutional and regulatory requirements.
Contact & Investigator
Julia Grapsa, MD PhD
PRINCIPAL INVESTIGATOR
Harvard Medical School (HMS and HSDM)
Frequently Asked Questions
Who can join the NCT07196930 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Valve Disease, Heart. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07196930 currently recruiting?
Yes, NCT07196930 is actively recruiting participants. Contact the research team at shehab.anwer@gmail.com for enrollment information.
Where is the NCT07196930 trial being conducted?
This trial is being conducted at Aswān, Egypt, Lisbon, Portugal.
Who is sponsoring the NCT07196930 clinical trial?
NCT07196930 is sponsored by Valvular Heart Disease in Women Registry. The principal investigator is Julia Grapsa, MD PhD at Harvard Medical School (HMS and HSDM). The trial plans to enroll 800 participants.